Intellectus Partners LLC Boosts Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellectus Partners LLC increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 26.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 74,525 shares of the company’s stock after purchasing an additional 15,700 shares during the quarter. Intellectus Partners LLC owned approximately 0.07% of Intellia Therapeutics worth $869,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. E Fund Management Co. Ltd. grew its holdings in Intellia Therapeutics by 10.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock valued at $210,000 after buying an additional 1,634 shares in the last quarter. Vestmark Advisory Solutions Inc. grew its stake in Intellia Therapeutics by 14.3% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 375,291 shares of the company’s stock valued at $4,376,000 after acquiring an additional 47,045 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Intellia Therapeutics during the fourth quarter valued at $4,793,000. Arizona State Retirement System lifted its stake in Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after purchasing an additional 1,615 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at about $213,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on NTLA shares. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group reiterated a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Oppenheimer dropped their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Wedbush restated a “neutral” rating and set a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Finally, William Blair reiterated a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 29,000 shares of company stock worth $352,551. Company insiders own 3.20% of the company’s stock.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $10.35 on Friday. The company has a market capitalization of $1.07 billion, a P/E ratio of -1.90 and a beta of 1.97. Intellia Therapeutics, Inc. has a fifty-two week low of $8.30 and a fifty-two week high of $32.00. The stock has a 50-day simple moving average of $10.61 and a 200-day simple moving average of $15.19.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.